1. A disease risk index for patients undergoing allogeneic stem cell transplantation
by Philippe Armand, Christopher J. Gibson, Corey Cutler, Vincent T. Ho, John Koreth, Edwin P. Alyea, Jerome Ritz, Mohamed L. Sorror, Stephanie J. Lee, H. Joachim Deeg, Barry E. Storer, Frederick R. Appelbaum, Joseph H. Antin, Robert J. Soiffer, and Haesook T. Kim
Blood
Volume 120(4):
July 26, 2012
©2012 by American Society of Hematology

2. OS after HSCT stratified by disease/status group and conditioning intensity.
OS after HSCT stratified by disease/status group and conditioning intensity. (A) MAC patients, (B) RIC patients, and (C) overall disease/status risk groups, all patients.
Philippe Armand et al. Blood 2012;120:
©2012 by American Society of Hematology

3. Outcomes of HSCT stratified by overall disease/status risk group.
Outcomes of HSCT stratified by overall disease/status risk group. (A) OS. (B) PFS. (C) Cumulative incidence of relapse. (D) Cumulative incidence of NRM.
Philippe Armand et al. Blood 2012;120:
©2012 by American Society of Hematology

4. Outcomes of patients in the validation cohort stratified by disease/status risk group.
Outcomes of patients in the validation cohort stratified by disease/status risk group. (A) OS. (B) PFS.
Philippe Armand et al. Blood 2012;120:
©2012 by American Society of Hematology